ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: Comparison with high-dose cyclophosphamide plus G-CSF

Bone Marrow Transplantation

Volumn 35, Issue 5, 2005, Pages 449-454

  Lee, J L ^a,b   Kim, S ^a   Kim, S W ^a   Kim, E K ^a   Kim, S B ^a   Kang, Y K ^a   Lee, J ^a   Kim, M W ^a   Park, C J ^a   Chi, H S ^a   Huh, J ^a   Kim, S H ^a   Suh, C ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

Cyclosphosphamide; ESHAP; Lymphoma; Mobilization

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MESNA; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DOSE TIME EFFECT RELATION; DRUG FATALITY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; HUMAN CELL; INFECTION; MALE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSORY DYSFUNCTION; SIDE EFFECT; SKELETON; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; THROMBOCYTE TRANSFUSION;

ADOLESCENT; ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 20144362352     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704798     Document Type: Article

References (27)

1. Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413.
2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
3. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18 3025-3030.
4. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
5. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
6. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The MD Anderson Cancer Center experience. Hematol Oncol Clin N Am 1997; 11: 937-947.
7. Petit J, Boque C, Cancelas JA et al. Feasibility of ESHAP+G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Leukemia Lymphoma 1999; 34: 119-127.
8. Berdeja JG, Ambinder RF, Jones RJ et al. Stem cell mobilization with G-CSF following standard ESHAP chemotherapy in patients with lymphoma. Blood 2001; 98: 456 (abstr. 754).
9. Watts MJ, Ings SJ, Leverett D et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 gm(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82 278-282.
10. Lee JL, Kim SB, Lee GW et al. The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Yonsei Med J 2003; 44: 800-810.
11. Lee JL, Kim SB, Lee GW et al. Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest. J Korean Med Sci 2003; 18 27-35.
12. Park KU, Kim SH, Suh C et al. Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 2001; 67: 42-47.
13. Suh C, Kim S, Kim S-H et al. Initiation of peripheral blood stem cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE-9000. Transfusion 2004; 44: 1762-1768.
14. Lee JL, Kim SB, Lee GW et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apheresis Sci 2003; 29: 29-37.
15. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
16. Pavone V, Gaudio F, Guarini A et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285-290.
17. Olivieri A, Offidani M, Ciniero L et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 1995; 16: 85-93.
18. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-3785.
19. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
20. Watts MJ, Sullivan AM, Ings SJ et al. Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures. Bone Marrow Transplant 1997; 20: 157-162.
21. Le Gouill S, Moreau P, Morineau N et al. Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study. Haematologica 2002; 87: 333-334.
22. Allan DS, Keeney M, Howson-Jan K et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-972.
23. Dreger P, Marquardt P, Haferlach T et al. Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950-957.
24. McQuaker IG, Haynes AP, Stainer C et al. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997; 98: 228-233.
25. Aurlien E, Holte H, Pharo A et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 873-878.
26. Weaver CH, Zhen B, Buckner CD. Treatment of patients with malignant lymphoma with mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplant 1998; 21: 1169-1170.
27. Zinzani PL, Barbieri E, Visani G et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 1994; 79: 508-512.